Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

United Therapeutics (UTHR) stock in plain English

Free brief · no signupStart here
UTHRPublished Nov 8, 2026
United Therapeutics Corp
Healthcare · Drug Manufacturers - Specialty & Generic
Develops and sells prescription drugs for severe pulmonary hypertension and lung fibrosis.
Assets:
Tyvaso inhalation franchiseDelivers treprostinil via dry powder inhalers and ultrasonic nebulizers
Remodulin product lineContinuous subcutaneous and intravenous treprostinil infusion therapies
Three xenograft facilitiesProduce pathogen-free cellular organs for human transplantation research
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

75
OPS ScoreOperating finances
Latest quote
-3.16%$559.10
$23.81B
21.1×
$3.19B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 08, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was UTHR. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does United Therapeutics (UTHR) do?

United Therapeutics Corp (UTHR) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Develops and sells prescription drugs for severe pulmonary hypertension and lung fibrosis. Manufactures inhaled and infused therapies for rare lung diseases while developing bioengineered transplantable organs. It is worth $23.81B on the market and sold $3.19B over the last year.

Market cap
$23.81B
P/E ratio
21.1×
Annual sales
$3.19B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 08, 2026

Brands and businesses behind UTHR

  • Tyvaso: Inhaled treprostinil solution and dry powder sold through specialty pharmacies to treat pulmonary arterial hypertension and interstitial lung disease.
  • Remodulin: Continuous subcutaneous or intravenous treprostinil formulation prescribed to reduce symptoms associated with severe pulmonary arterial hypertension.
  • Orenitram: Extended-release oral treprostinil tablets prescribed to improve exercise capacity in patients living with pulmonary arterial hypertension.
  • Unituxin: Monoclonal antibody injection administered in combination therapy to treat pediatric patients with high-risk neuroblastoma.

UTHR’s flags, in plain English

Each flag is a number from United Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.

Stupid Cash

Can pay this year's bills 4.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 0% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Fat Margins

Profit margin of 38.6%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

One Big Customer

Most commercial revenue depends on treprostinil formulations that face ongoing generic patent challenges. A large share of sales comes from a single customer. If that customer leaves or buys less, sales drop with it.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about UTHR

How big is United Therapeutics?

United Therapeutics’ market cap is $23.81B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.19B: what customers paid the company over the last year, before any costs.

What is UTHR’s P/E ratio?

UTHR’s P/E ratio is 21.1×. Investors pay about 21.1 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with UTHR?

The first risk note on the card is One Big Customer, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From United Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. UTHR’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card